SABS — SAB Biotherapeutics Share Price
0.000.00%
Last trade - 00:00- $14.86m
- -$2.20m
- $1.32m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.57 | ||
| Price to Tang. Book | 0.57 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.24 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -118.48% | ||
| Return on Equity | -81.92% | ||
| Operating Margin | -3244.87% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 55.24 | 60.88 | 23.9 | 2.24 | 1.32 | 0.67 | 1 | -60.66% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 12th, 2020
- Public Since
- January 12th, 2021
- No. of Shareholders
- 254
- No. of Employees
- 63
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 9,288,868
- Address
- 777 W 41St St, Suite 401, MIAMI BEACH, 33140
- Web
- https://www.sab.bio/
- Phone
- +1 3058452813
- Auditors
- EisnerAmper LLP
Upcoming Events for SABS
SAB Biotherapeutics Inc Annual Shareholders Meeting
Q2 2025 SAB Biotherapeutics Inc Earnings Release
Q3 2025 SAB Biotherapeutics Inc Earnings Release
Similar to SABS
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the SAB Biotherapeutics share price?
As of Today at 23:01 UTC, shares in SAB Biotherapeutics are trading at $1.60. This share price information is delayed by 15 minutes.
How has the SAB Biotherapeutics share price performed this year?
Shares in SAB Biotherapeutics last closed at $1.60 and the price had moved by -60.2% over the past 365 days. In terms of relative price strength the SAB Biotherapeutics share price has underperformed the S&P500 Index by -64.11% over the past year.
What are the analyst and broker recommendations for SAB Biotherapeutics?
The overall consensus recommendation for SAB Biotherapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the SAB Biotherapeutics dividend yield?
SAB Biotherapeutics does not currently pay a dividend.
Does SAB Biotherapeutics pay a dividend?
SAB Biotherapeutics does not currently pay a dividend.
When does SAB Biotherapeutics next pay dividends?
SAB Biotherapeutics does not currently pay a dividend.
How do I buy SAB Biotherapeutics shares?
To buy shares in SAB Biotherapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of SAB Biotherapeutics?
As of the previous close price of $1.60, shares in SAB Biotherapeutics had a market capitalisation of $14.86m.
Where are SAB Biotherapeutics shares listed?
Here are the trading details for SAB Biotherapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SABS
What kind of share is SAB Biotherapeutics?
Based on an overall assessment of its quality, value and momentum SAB Biotherapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a SAB Biotherapeutics share price forecast for 2025?
The analyst consensus target price for shares in SAB Biotherapeutics is $9.00. That is 462.5% above the last closing price of $1.60.
Analysts covering SAB Biotherapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.98 for the next financial year.
Find out moreWhat is the trend in the SAB Biotherapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SAB Biotherapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -58.57%.
As of the last closing price of $1.60, shares in SAB Biotherapeutics were trading -39.01% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the SAB Biotherapeutics PE Ratio?
The SAB Biotherapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of SAB Biotherapeutics?
We do not have data on SAB Biotherapeutics' directors